TY - JOUR
T1 - Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia
AU - Brinkerhoff, Brian T.
AU - Choong, Nicholas W.
AU - Treisman, Jonathan S.
AU - Poetker, David M.
PY - 2012/5
Y1 - 2012/5
N2 - Current treatment of severe epistaxis in patients with hereditary hemorrhagic telangiectasia is not durable in reducing the frequency and severity of bleeds. Recent reports have demonstrated marked improvement of epistaxis with administration of either intravenous or topical bevacizumab. We present the long-term outcome of a patient who received repeated treatments of intravenous bevacizumab followed by maintenance intranasal bevacizumab. We demonstrate durable control of epistaxis with intranasal bevacizumab. This allows delivery of bevacizumab effectively, reduces cost, and obviates the risk of systemic adverse effects related to bevacizumab.
AB - Current treatment of severe epistaxis in patients with hereditary hemorrhagic telangiectasia is not durable in reducing the frequency and severity of bleeds. Recent reports have demonstrated marked improvement of epistaxis with administration of either intravenous or topical bevacizumab. We present the long-term outcome of a patient who received repeated treatments of intravenous bevacizumab followed by maintenance intranasal bevacizumab. We demonstrate durable control of epistaxis with intranasal bevacizumab. This allows delivery of bevacizumab effectively, reduces cost, and obviates the risk of systemic adverse effects related to bevacizumab.
UR - http://www.scopus.com/inward/record.url?scp=84860378849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860378849&partnerID=8YFLogxK
U2 - 10.1016/j.amjoto.2011.07.012
DO - 10.1016/j.amjoto.2011.07.012
M3 - Article
C2 - 21917353
AN - SCOPUS:84860378849
SN - 0196-0709
VL - 33
SP - 349
EP - 351
JO - American Journal of Otolaryngology - Head and Neck Medicine and Surgery
JF - American Journal of Otolaryngology - Head and Neck Medicine and Surgery
IS - 3
ER -